Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib
- PMID: 20700898
- DOI: 10.1038/nrclinonc.2010.113
Targeted therapies: Activated PI3K/AKT confers resistance to trastuzumab but not lapatinib
Comment on
-
Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib.Mol Cancer Ther. 2010 Jun;9(6):1489-502. doi: 10.1158/1535-7163.MCT-09-1171. Epub 2010 May 25. Mol Cancer Ther. 2010. PMID: 20501798
References
-
- Mol Cancer Ther. 2010 Jun;9(6):1489-502 - PubMed
Publication types
LinkOut - more resources
Full Text Sources
